Qvella_Logo_Tagline_2Color_RGBQvella_Logo_Tagline_2Color_RGBQvella_Logo_Tagline_2Color_RGBQvella_Logo_Tagline_2Color_RGB
  • Home
  • Sepsis
  • FAST System
  • FAST System Resources
  • FAST-ID BSI
  • News & Events
  • Leadership
  • Careers
  • Contact
  • Home
  • Sepsis
  • FAST System
  • FAST System Resources
  • FAST-ID BSI
  • News & Events
  • Leadership
  • Careers
  • Contact
✕

Press release

Qvella announced today that it has completed a US$20 million Series A financing. The round of funding was co-led by RA Capital Management and Whitecap Venture Partners, and includes Hatteras Venture Partners and Sands Capital Ventures as syndicate partners. The funds will be used by Qvella to finance ongoing product development and team expansion.

Learn More

Related posts

April 22, 2022

Qvella FAST™ System and FAST-PBC Prep™ Cartridge Get CE Marked and FDA Listed for In Vitro Diagnostic Use


Read more
March 21, 2022

DGHM 2022


Read more
March 21, 2022

RICAI 2022


Read more

Qvella’s Vision is to Enable Faster Clinical Decisions for Better Patient Outcomes

Last updated on March 9, 2022

QUICK LINKS

  • Home
  • Sepsis
  • FAST System
  • FAST System Resources
  • FAST-ID BSI
  • News & Events
  • Leadership
  • Careers
  • Privacy Policy
  • Terms & Conditions

GET IN TOUCH

Qvella Corporation Headquarters:
9133 Leslie Street, Unit 110
Richmond Hill, ON L4B 4N1
Canada

Tel: (833) 478-3552

Qvella Corporation USA:
2035 Corte del Nogal,  Suite 105
Carlsbad, CA 92011
United States
Tel: (833) 478-3552

Qvella Corporation Europe:
Generaal de Wittelaan 17C
2800 Mechelen
Belgium
Tel: +32 473 59 32 36

© 2022 Qvella Corporation. All Rights Reserved.